1 – 20 of 20
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease
(
- Contribution to journal › Article
-
Mark
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold : SAR of the Aryloxyaryl Moiety
(
- Contribution to journal › Article
-
Mark
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia
(
- Contribution to journal › Article
-
Mark
Large-Scale Crystallographic Fragment Screening Expedites Compound Optimization and Identifies Putative Protein-Protein Interaction Sites
(
- Contribution to journal › Article
- 2021
-
Mark
Development of Novel VEGFR2 Inhibitors Originating from Natural Product Analogues with Antiangiogenic Impact
(
- Contribution to journal › Article
-
Mark
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold : SAR of the Biphenyl Moiety
(
- Contribution to journal › Article
- 2020
-
Mark
In Vivo Veritas : 18F-Radiolabeled Glycomimetics Allow Insights into the Pharmacological Fate of Galectin-3 Inhibitors
(
- Contribution to journal › Article
- 2018
-
Mark
Systematic Tuning of Fluoro-galectin-3 Interactions Provides Thiodigalactoside Derivatives with Single-Digit nM Affinity and High Selectivity
(
- Contribution to journal › Article
- 2016
-
Mark
A Selective Galactose–Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model
(
- Contribution to journal › Article
-
Mark
Preclinical Characterization of 3β-(N-Acetyl l -cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Active Site Mapping of an Aspartic Protease by Multiple Fragment Crystal Structures : Versatile Warheads to Address a Catalytic Dyad
(
- Contribution to journal › Article
- 2012
-
Mark
Selective mode of action of guanidine-containing non-peptides at human NPFF receptors
(
- Contribution to journal › Article
- 2009
-
Mark
Discovery of selective nonpeptidergic neuropeptide FF2 receptor agonists
(
- Contribution to journal › Article
-
Mark
Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators
(
- Contribution to journal › Article
-
Mark
Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor β ligands
(
- Contribution to journal › Article
-
Mark
Synthesis and evaluation of dibenzothiazepines : A novel class of selective cannabinoid-1 receptor inverse agonists
(
- Contribution to journal › Article
- 2008
-
Mark
Discovery of potent and selective small-molecule PAR-2 agonists
(
- Contribution to journal › Article
- 2006
-
Mark
Novel potent and efficacious nonpeptidic urotensin II receptor agonists
(
- Contribution to journal › Article
- 2005
-
Mark
Discovery of a potent, orally available, and isoform-selective retinoic acid β2 receptor agonist
(
- Contribution to journal › Article
- 2002
-
Mark
Discovery of the first nonpeptide agonist of the GPR14/Urotensin-II receptor : 3-(4-Chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one (AC-7954)
(
- Contribution to journal › Article